If you are a woman in your 40s, 50s, or early 60s, you have probably heard two versions of testosterone. One says it is only a libido drug. The other says it will rebuild bone, muscle, and a sharper brain.
Desire matters. So do bone, strength, and thinking. Androgen receptors sit in skeletal muscle, bone, brain, and genital tissue, so those questions are fair. The evidence behind them is not equal. Sexual function has the strongest randomized support. Bone, muscle, and cognition are plausible biology with thinner proof. I use testosterone for selected women after history, exam, labs, and a goal we can measure.
What testosterone does in women
Women make testosterone in the ovaries and adrenal glands. Levels tend to decline gradually from early adulthood. Natural menopause is mainly an estradiol story, not an abrupt testosterone cliff. Bilateral oophorectomy can cut ovarian androgen contribution more suddenly.
Testosterone acts through androgen receptors and, in some tissues, after aromatase converts it to estradiol. When I prescribe it, the aim is physiologic female-range exposure, not a male dose.
In the United States there is still no FDA-approved testosterone product labeled for female sexual dysfunction, or for bone, muscle, or cognition in women. Prescribing for postmenopausal hypoactive sexual desire disorder (HSDD, distressingly low desire) is off-label. Off-label can be appropriate. It requires informed consent, a sensible product and route, and follow-up.
Where the randomized evidence is strongest
A 2019 systematic review and meta-analysis of randomized trials by Islam and colleagues found that testosterone improved desire, arousal, pleasure, and satisfying sexual events, and reduced sexual distress, compared with placebo or a comparator. Acne and increased hair growth also rose. That belongs in the consent conversation.
The 2019 Global Consensus Position Statement by Davis and colleagues, endorsed by societies including the Endocrine Society and ISSWSH, concluded that HSDD is the indication with sufficient evidence to support treatment in postmenopausal women after a proper assessment.
"Just about libido" gets the emphasis backward. Sexual function is the best-proven reason in pooled randomized data. Bone, muscle, and thinking are reasonable questions. They do not have the same trial support.
For a fuller map of sexual function versus other domains, see Is Testosterone for Women Only About Libido?.
Bone: an early signal, not an osteoporosis drug
Two randomized trials from 1995 each showed an additive bone-density signal when testosterone was added to estrogen.
Davis and colleagues randomized postmenopausal women to estradiol implants alone or estradiol plus testosterone implants for two years. Bone mineral density rose in both groups. The combined group gained more at several sites.
Watts and colleagues studied surgically menopausal women on oral esterified estrogen alone or the same estrogen plus low-dose oral methyltestosterone for two years. Estrogen alone held spinal bone mineral density. Estrogen plus methyltestosterone increased spinal BMD from baseline.
One trial used implants. One used oral methyltestosterone. Neither is a freestanding osteoporosis indication.
The 2019 Global Consensus concluded that available pooled randomized data do not support an effect of testosterone on spine, total hip, or femoral neck bone mineral density at the durations reviewed, and it called for better musculoskeletal trials. Vitamin D and calcium when indicated, fall prevention, and proven osteoporosis therapies still carry the bone plan. Testosterone does not replace that plan.
Muscle, frailty, and what I will not claim
Frailty is why muscle belongs here.
In the Women's Health Initiative Observational Study, Woods and colleagues found that frailty in women 65 and older tracked with higher risks of death, disability, hip fracture, and hospitalization. In the Study of Osteoporotic Fractures, Ensrud and colleagues linked frailty to falls, fracture, and mortality. Beaudart and colleagues' meta-analysis associates sarcopenia (age-related low muscle) with higher mortality and worse functional outcomes.
The testosterone studies do not close that gap. In the Davis 1995 implant trial, fat-free mass rose with combined estradiol and testosterone, not with estradiol alone. Pooled randomized analyses used by the Global Consensus did not show a statistically significant effect of physiologic-dose testosterone on lean body mass, total body fat, or muscle strength. A 2023 observational systematic review by Taylor and colleagues likewise did not support a clear association between a woman's total testosterone and muscle mass, strength, or performance.
Testosterone alone has not been shown to prevent frailty or death. When testosterone belongs in the plan, I prescribe it with adequate protein and strength training, not instead of them. I still screen for weakness and unintentional weight loss.
Brain and cognition, kept small
Clearer thinking after hormone care is a report I hear. It is not proof that testosterone prevents dementia.
The Global Consensus found insufficient evidence that testosterone improves cognition, and no benefit for general wellbeing or depressed mood in the pooled randomized data available in 2019. A 2023 observational systematic review by Sultana and colleagues leaves the link between testosterone and cognitive performance incomplete.
Hernandez and colleagues (2026), working with Newson Research in the UK and Baylor College of Medicine urology (Khera and colleagues), reported a single-center retrospective cohort, not a randomized trial. They reviewed 279 women, mean age about 56, already on transdermal estrogen for at least three months, who then added transdermal testosterone, mostly AndroFeme 1%. Symptoms were re-scored at roughly three months on a modified Greene Climacteric Scale, not the standardized instrument alone. There was no control group. Some women also had estrogen dose changes, which confounds attribution.
Fifteen of 24 symptoms improved, including vaginal dryness (about 59%), hot flashes (about 55%), and libido (about 55%), with gains also reported in energy, musculoskeletal comfort, mood, and cognitive symptom scores. Neuropathic and cardiopulmonary symptoms did not improve.
That cohort can keep energy, mood, and cognitive symptoms on the research list. It is not randomized proof, and it does not support a claim that testosterone prevents cognitive decline. Sleep, blood pressure, blood sugar, and daily habits still matter more for the brain than any single hormone.
Labs, route, and safety
There is no testosterone number that means "you need this," the way a glucose threshold can diagnose diabetes. Distressingly low desire is a clinical diagnosis. A level helps exclude a high baseline and, if we treat, confirms that exposure stays in a female treatment range.
I am more likely to discuss testosterone when a postmenopausal woman has HSDD after other contributors are addressed, and she accepts monitoring. I am less likely when the only goal is denser bone or sharper memory.
Female-range therapy is not male-range therapy. More is not better. I watch for acne, increased facial or body hair, scalp thinning in susceptible women, oily skin, voice deepening, and clitoral enlargement. Most improve when exposure is lowered. If hair thinning is already part of your story on hormone therapy, dose is one factor among several: Your Hair Is Thinning on Hormone Therapy. Testosterone Isn't Always the Reason.
Route matters for lipids. In the Watts 1995 oral trial, the methyltestosterone arm lowered HDL cholesterol while estrogen alone raised it. The Global Consensus advises against oral testosterone routes for that lipid reason. Physiologic-dose nonoral routes have not shown short-term adverse lipid effects in the pooled data.
These trials are generally too short and too small to settle lifelong cardiovascular or cancer outcomes. Testosterone therapy has not been shown to increase a woman's risk of breast cancer. It is also not a breast cancer prevention drug. Some clinicians have used androgen therapy in selected breast cancer settings. That is specialized oncology practice, not a reason for wellness-dose testosterone in healthy women. Active or prior hormone-sensitive cancer belongs with oncology-aligned specialty care.
Pregnancy and breastfeeding are exclusions. Unexplained bleeding, significant liver disease, or uncontrolled cardiovascular risk need evaluation first. Monitoring covers how you feel, androgenic side effects, and follow-up levels.
Testosterone will not repair sleep debt, untreated thyroid disease, iron deficiency, or relationship distress. Those still come first.
What this looks like in clinic
A woman in her early 50s came in after reading that testosterone would rebuild her bone and sharpen her brain. Libido was low and distressing. Energy was flat. She was already on estrogen. She wanted a higher dose than female-range therapy usually uses, and a guarantee on her next DEXA.
We did not start there. Sexual function had the firmest randomized footing. Bone and cognition were still incompletely tested. Female-range monitoring was required. Desire and energy improved. Strength moved more with training and protein than she expected.
Where to take this next
If you are already a patient at a 4Ever Young clinic, take this information to your clinic team. Talk with the clinical staff who already know you and your history. I support that care.
If you are not located near a 4Ever Young clinic and would like to just have a conversation with me virtually, email me at drwilcox@precisionhormoneconsulting.com or DM @wellnessdoc_4everyoung on Instagram.
Darrell Wilcox, MD | @wellnessdoc_4everyoung on Instagram
Wellness Doc · 4Ever Young
Sources
Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019. PMID: 31353194.
Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019. PMID: 31498871.
Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995. PMID: 7616872.
Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol. 1995. PMID: 7898828.
Taylor S, Islam RM, Bell RJ, Hemachandra C, Davis SR. Endogenous testosterone concentrations and muscle mass, strength and performance in women, a systematic review of observational studies. Clin Endocrinol (Oxf). 2023. PMID: 36585396.
Sultana F, Davis SR, Bell RJ, Taylor S, Islam RM. Association between testosterone and cognitive performance in postmenopausal women: a systematic review of observational studies. Climacteric. 2023. PMID: 36366914.
Hernandez BS, Boyne AM, Fleming B, et al. Improvement in multiple organ systems following testosterone replacement therapy in women previously on standard hormone replacement therapy. J Sex Med. 2026. PMID: 42673112.
Woods NF, LaCroix AZ, Gray SL, et al. Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc. 2005. PMID: 16078957.
Ensrud KE, Ewing SK, Taylor BC, et al. Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci. 2007. PMID: 17634322.
Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyère O. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS One. 2017. PMID: 28095426.
This content is for educational purposes only and does not constitute medical advice. Hormone and lab decisions deserve individualized evaluation with a licensed clinician who knows your history. No outcome is guaranteed. Dr. Wilcox is licensed to practice in Texas, Arizona, Colorado, Oregon, and Florida.
